Equities

SyntheticMR AB (publ)

SyntheticMR AB (publ)

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Feb 28 2019.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.

  • Revenue in SEK (TTM)81.53m
  • Net income in SEK4.72m
  • Incorporated2007
  • Employees43.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.